Specialty chemical stock jumps after signing LoI with US based firm for supply of advanced solvent for EV batteriesSpecialty chemical stock jumps after signing LoI with US based firm for supply of advanced solvent for EV batteries

Introduction:

Specialty chemical stock has secured a key agreement to develop and supply an advanced electrolyte solvent for EV batteries. This strategic move expands its presence in battery chemicals, driving revenue growth while supporting next-generation battery technology and sustainable energy solutions in the EV market.

Share Price movement of Anupam Rasayan India :

On February 28, 2025, Anupam Rasayan India Limited opened at ₹621.25, reaching a high of ₹643.80, up 1.23% from its previous close of ₹628.25, and a low of ₹601.00. Currently, it is trading at ₹636.00, with a market cap of ₹6,991.63 crore.

Anupam Rasayan signed new LoI:

Anupam Rasayan India Ltd. has signed a Letter of Intent (LOI) with U.S.-based Elementium Materials Inc. to develop and supply an advanced electrolyte solvent for EV batteries. The supply is expected to begin by the end of FY26, with potential sales of $350-$450 million over five years.  

The collaboration aligns with Anupam Rasayan’s strategy to expand into battery chemicals and work directly with OEMs. The new product aims to enhance battery performance, improve power output, and contribute to affordable clean energy, requiring a new plant for full-scale production.  

Elementium Materials’ CEO, Dr. Matthew Dawson, emphasized that the partnership strengthens their global supply chain, enabling rapid production scaling for next-generation battery technology. The agreement is expected to boost Anupam Rasayan’s revenue growth while supporting sustainable energy solutions for the EV market.

Also Read: Stock jumps 3% after receiving order worth ₹12.5 Cr from Gujarat Energy Transmission Corp

Recent news About Anupam Rasayan India :

Anupam Rasayan India reported a 53% increase in consolidated net profit during the third quarter of FY25, amounting to ₹28.19 crore, compared to ₹18.4 crore in the same period the previous year. This robust financial performance reflects the company’s effective strategies and strong market position. 

Ace investor holding of Anupam Rasayan India :

Milan R Thakkar holds an 18.96% stake in Anupam Rasayan India Ltd., owning 20,847,326 shares valued at ₹1,325.9 crore. His holding slightly declined by 0.03% from the previous quarter, indicating a minor portfolio adjustment while maintaining a significant investment in the company.  

Jayeshkumar Virendrabhai Patel owns a 1.13% stake in Anupam Rasayan India Ltd., holding 1,241,394 shares valued at ₹79.0 crore. His stake also decreased by 0.03% compared to the last quarter, suggesting a small reduction in his holding while remaining invested in the stock.

Stock performance of Anupam Rasayan India  for Period of 1 week, 6 months and 1 year:

Anupam Rasayan India’s stock declined by 1.84% over the past week, reflecting short-term weakness. Over six months, it dropped 19.3%, indicating continued downward pressure. The one-year performance shows a significant decline of 34.3%, highlighting persistent challenges impacting investor sentiment and stock movement.

Also Read: EV stock to watch after it sells 25,000 EVs in February 2025; Maintains 28% market share

Shareholding pattern of Anupam Rasayan India :

All values in %	Dec-24	Sep-24	Jun-24
Promoters	61.18	61.23	61.23
FII	7.46	7	7.14
DII	2.32	2.3	2.65
Retail & others	29.06	29.47	28.97

About Anupam Rasayan India :

Anupam Rasayan India Ltd (NSE:ANURS) is a leading specialty chemicals manufacturer focused on custom synthesis and contract manufacturing. It serves global industries like agrochemicals, pharmaceuticals, and personal care, leveraging advanced R&D and sustainable processes to deliver high-value chemical solutions for diverse applications.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.